Adnan Custovic1, Lars Soderstrom, Staffan Ahlstedt, Peter D Sly, Angela Simpson, Patrick G Holt. 1. University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom. adnan.custovic@manchester.ac.uk
Abstract
BACKGROUND: An increase in IgE antibody levels to inhalant allergens is associated with an increased likelihood of wheezing. The role of allergen-specific IgG and IgG4 in relation to wheezing is yet to be determined. OBJECTIVE: We sought to investigate whether Fel d 1-specific IgG and IgG4 antibodies modify the association between cat allergen-specific IgE and childhood wheezing. METHODS: We used data from 2 population-based birth cohorts (United Kingdom [UK], n = 473; Australia, n = 1336). Current wheeze was defined as wheezing in the previous 12 months at age 5 (UK) and 14 (Australia) years. We determined cat allergen-specific IgE (whole extract) and IgG and IgG4 antibody (purified rFel d 1) levels and used logistic regression to estimate the relationship between wheeze and the quantitative allergen antibody levels. RESULTS: In the univariate analysis risk of wheezing increased significantly with increasing cat-specific IgE levels (UK: odds ratio [OR], 1.56; 95% CI, 1.28-1.90; Australia: OR, 1.29; 95% CI, 1.19-1.40). rFel d 1-specific IgG or IgG4 had no significant effect on wheeze in either population. However, a different pattern of the relationship between antibody levels and wheezing emerged in the multivariate analysis. In the UK cat-specific IgE increased the risk of wheeze (OR, 2.01; 95% CI, 1.29-3.12; P = .002), whereas rFel d 1-specific IgG decreased the risk (OR, 0.46; 95% CI, 0.21-0.99; P = .05). This finding was replicated in Australia (IgE: OR, 1.46; 95% CI, 1.28-1.68; P < .001; IgG: OR, 0.66; 95% CI, 0.44-0.99; P = .049). There was no significant association between IgG4 antibody levels and wheezing in either population. CONCLUSIONS: rFel d 1-specific IgG but not IgG4 antibody levels significantly modify the association between cat-specific IgE and childhood wheezing, with the risk of symptoms decreasing with increasing IgG levels.
BACKGROUND: An increase in IgE antibody levels to inhalant allergens is associated with an increased likelihood of wheezing. The role of allergen-specific IgG and IgG4 in relation to wheezing is yet to be determined. OBJECTIVE: We sought to investigate whether Fel d 1-specific IgG and IgG4 antibodies modify the association between cat allergen-specific IgE and childhood wheezing. METHODS: We used data from 2 population-based birth cohorts (United Kingdom [UK], n = 473; Australia, n = 1336). Current wheeze was defined as wheezing in the previous 12 months at age 5 (UK) and 14 (Australia) years. We determined cat allergen-specific IgE (whole extract) and IgG and IgG4 antibody (purified rFel d 1) levels and used logistic regression to estimate the relationship between wheeze and the quantitative allergen antibody levels. RESULTS: In the univariate analysis risk of wheezing increased significantly with increasing cat-specific IgE levels (UK: odds ratio [OR], 1.56; 95% CI, 1.28-1.90; Australia: OR, 1.29; 95% CI, 1.19-1.40). rFel d 1-specific IgG or IgG4 had no significant effect on wheeze in either population. However, a different pattern of the relationship between antibody levels and wheezing emerged in the multivariate analysis. In the UK cat-specific IgE increased the risk of wheeze (OR, 2.01; 95% CI, 1.29-3.12; P = .002), whereas rFel d 1-specific IgG decreased the risk (OR, 0.46; 95% CI, 0.21-0.99; P = .05). This finding was replicated in Australia (IgE: OR, 1.46; 95% CI, 1.28-1.68; P < .001; IgG: OR, 0.66; 95% CI, 0.44-0.99; P = .049). There was no significant association between IgG4 antibody levels and wheezing in either population. CONCLUSIONS: rFel d 1-specific IgG but not IgG4 antibody levels significantly modify the association between cat-specific IgE and childhood wheezing, with the risk of symptoms decreasing with increasing IgG levels.
Authors: Hayley Jeal; Adrian Draper; Jessica Harris; Anthony Newman Taylor; Paul Cullinan; Meinir Jones Journal: Am J Respir Crit Care Med Date: 2006-04-07 Impact factor: 21.405
Authors: B M Simpson; A Custovic; A Simpson; C L Hallam; D Walsh; H Marolia; J Campbell; A Woodcock Journal: Clin Exp Allergy Date: 2001-03 Impact factor: 5.018
Authors: Elysia M Hollams; Marie Deverell; Michael Serralha; Devinda Suriyaarachchi; Faith Parsons; Guicheng Zhang; Nicholas de Klerk; Barbara J Holt; Claire Ladyman; Agata Sadowska; Julie Rowe; Richard Loh; Peter D Sly; Patrick G Holt Journal: J Allergy Clin Immunol Date: 2009-09 Impact factor: 10.793
Authors: A M Witteman; S O Stapel; D H Sjamsoedin; H M Jansen; R C Aalberse; J S van der Zee Journal: Int Arch Allergy Immunol Date: 1996-04 Impact factor: 2.749
Authors: J A Wisniewski; R Agrawal; S Minnicozzi; W Xin; J Patrie; P W Heymann; L Workman; T A Platts-Mills; T W Song; M Moloney; J A Woodfolk Journal: Clin Exp Allergy Date: 2013-10 Impact factor: 5.018
Authors: Thomas A E Platts-Mills; Peter W Heymann; Scott P Commins; Judith A Woodfolk Journal: Ann Allergy Asthma Immunol Date: 2016-03 Impact factor: 6.347
Authors: Amanda K Rudman Spergel; Michelle L Sever; Jacqueline Johnson; Michelle A Gill; Veronique Schulten; April Frazier; Carolyn M Kercsmar; Stephanie Lovinsky-Desir; Dan A Searing; Alessandro Sette; Baomei Shao; Stephen J Teach; James E Gern; William W Busse; Alkis Togias; Robert A Wood; Andrew H Liu Journal: Pediatr Allergy Immunol Date: 2021-03-20 Impact factor: 5.464
Authors: Leon M Straker; Graham L Hall; Jenny Mountain; Erin K Howie; Elisha White; Nigel McArdle; Peter R Eastwood Journal: BMC Public Health Date: 2015-07-14 Impact factor: 3.295
Authors: L Hesse; N van Ieperen; C Habraken; A H Petersen; S Korn; T Smilda; B Goedewaagen; M H Ruiters; A C van der Graaf; M C Nawijn Journal: Allergy Date: 2018-01-31 Impact factor: 13.146
Authors: Michelle L Townsend; Angelique Riepsamen; Christos Georgiou; Victoria M Flood; Peter Caputi; Ian M Wright; Warren S Davis; Alison Jones; Theresa A Larkin; Moira J Williamson; Brin F S Grenyer Journal: PLoS One Date: 2016-03-18 Impact factor: 3.240